UBC Medical Indonesia Tbk. vs Solusi Bangun Indonesia Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp174 (market cap 691.25B, 635.5K 24h volume), while Solusi Bangun Indonesia Tbk. trades at Rp775 (market cap 6.99T). The key difference: Solusi Bangun Indonesia Tbk. is far larger — about 10.1× UBC Medical Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| LABS | SMCB | |
|---|---|---|
Market Cap | 691.25B | 6.99T |
Volume | 635.5K | — |
Lot | 6.36K | — |
Turnover | 110.15M | — |
Average Price | 173.33 | — |
Value | 110.15M | — |
Indicative Equilibrium Price | 174 | — |
Indicative Equilibrium Volume | 50 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →PT Holcim Indonesia Tbk (the Company) was originally a joint venture between a subsidiary of Kaiser Cement and Gypsum Corp. and PT Semen Gresik. Founded in 1971, the company owns a factory in Narogong, West Java, with an annual capacity of 3 million tons. The Company changed its foreign capital investment status (PMA) to domestic capital investment (PMDN) based on the approval from Chairman of Capital Investment Coordinating Board No. 17/V/1988 dated November 19, 1988. Effective January 1, 2006, the Company changed its name from PT Semen Cibinong Tbk. to PT Holcim Indonesia Tbk.
Read more on SMCB →